The global Marburg virus disease therapeutics market is expected to garner a market value of US$ 90.74 Million in 2023 and is expected to accumulate a market value of US$ 155 Million by registering a CAGR of 5.5% in the forecast period 2023 to 2033. The growth of the Marburg virus disease therapeutics market can be attributed to the increasing prevalence of the Marburg virus in different geographical regions. The demand for Marburg virus disease therapeutics registered a CAGR of 4.1% in the historical period 2018 to 2022
The Marburg virus disease market is expected to witness growth owing to the increasing prevalence of the ailment. In addition, the COVID-19 virus is fueling research and development activities for innovating therapeutics treatment for the Marburg virus diseases therapeutics market.
| Data Points | Key Statistics |
|---|---|
| Expected Market Value (2023) | US$ 90.74 Million |
| Anticipated Forecast Value (2033) | US$ 155 Million |
| Projected Growth Rate (2023 to 2033) | 5.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Marburg virus disease therapeutics reflected a value CAGR of 4.1% during the historic period, 2018 to 2022.
The similar symptoms of COVID-19 and Marburg virus diseases have created tremendous pressure on the healthcare industries, especially in the Middle East and South Africa. Thus, the demand for innovative treatments to reduce the intensity of the viruses is expected to boost the overall market in the upcoming years.
Furthermore, extensive research and development for innovating therapeutics are favoring the market's growth. Thus, the Marburg virus disease therapeutics market is expected to register a CAGR of 5.5% in the forecast period 2023 to 2033.
Exposure to the Marburg virus increases cases of contracting the virus among people
The rise in the healthcare sector globally is escalating the growth of the Marburg virus disease market. Marburg virus refers to the type of virus that belongs to the genus Marburgvirus in the family Filoviridae. This virus causes a severe viral disease that is known as Marburg virus disease (MHF), in both humans and nonhuman primates. MHF is generally characterized by systemic viral replication, abnormal inflammatory responses, and immunosuppression, similar to the Ebola virus.
Marburg can spread through human-to-human transmission via direct contact (through broken skin or mucous membranes) with the blood, secretions, organs, or other bodily fluids of infected people, and with surfaces and materials (e.g. bedding, and clothing) contaminated with these fluids. Thus, these factors are increasing the cases of the Marburg virus disease across the globe.
Increase in the prevalence of unhealthy lifestyles along with research and development efforts contributing to market growth
The surge in the number of people suffering from Marburg virus disease across the globe is one of the major factors driving the growth of the Marburg virus disease market. The rise in awareness among people regarding rare disorders and increased demand for various drugs for treating symptoms such as nausea, vomiting, chest pain, diarrhea, and jaundice, among others accelerate the market growth.
The rise in the number of clinical trials for the enhancement of drugs and therapies and the increase in the prevalence of unhealthy lifestyles of people further influence the market. Additionally, growth in awareness, the surge in investments, development in technology, change in lifestyle and rise in healthcare expenditure positively affect the Marburg virus disease market. Furthermore, advancements in medications extend profitable opportunities to the market players in the forecast period of 2023 to 2033.
Principal Consultant
Lack of awareness amongst people and the expensive nature of treatment derailing market growth
On the other hand, the high cost associated with the treatment and diagnosis is expected to obstruct market growth. Moreover, the expenditure required for investing in research and development for innovating therapeutics for treating the Marburg virus is more. This, in turn, is hampering the growth of the market.
Low awareness among people is projected to challenge the Marburg virus disease market in 2023 to 2023. Thus. Late detection of the ailment reduces the chances of receiving proper treatment to cure the ailment. All these factors are creating obstacles to the growth of the Marburg virus diseases therapeutics market.
Investment in research and development by key players favoring the market growth
North America dominates the Marburg virus disease market due to the advanced medical care system and infrastructure within the region. Moreover, the increasing prevalence of Marburg viral diseases in the region is bolstering the need for therapeutics.
Furthermore, the strong presence of key players in the region is favoring the growth of the market. Investment in research and development to innovate novel therapeutic treatment is another factor driving the growth of the market. the presence of research institutes in the USA. and Canada is bolstering the growth of the Marburg virus diseases therapeutics market in North America. Thus, North America is expected to possess a 43% market share of the Marburg virus diseases therapeutics market in North America in 2023.
Absence of Vaccines increasing dependability on Therapeutics Treatment
Owing to the increasing predominance of Ebola Virus Disease (EVD) or Ebola Virus disease and Marburg Virus Disease (MVD) or Marburg Virus disease, caused by filoviruses termed Ebola virus and Marburg virus in African countries like Guinea, the Democratic Republic of the Congo, Uganda, Angola, Kenya, and South Africa, as per updates by World Health Organization (WHO), in the Rest of the world region.
Ebola & Marburg Infections market growth is being driven by the increasing Ebola outbreaks in Guinea which then spread to Sierra Leone and Liberia and cases of Marburg Virus Disease (MVD) in Uganda and Angola. The Democratic Republic of the Congo, Kenya, and South Africa. However, as per World Health Organization (WHO), presently, there are no vaccines or antiviral treatments certified for Marburg Virus Disease (MVD) or Marburg Virus disease, which is one of the major factors hampering the growth of the Ebola & Marburg Infections Market. Thus, the Middle East and Africa are expected to possess a 39% market share for Marburg viral disease therapeutic treatment market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of end users, the Marburg virus diseases market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centres, and Others. The hospital segment is expected to hold the largest market share for Marburg virus disease therapeutics. This is owing to the availability of various treatments and diagnostics in hospitals. In addition, the presence of healthcare experts and cardiologists plays a key role in the wide usage of hospitals for the treatment of Marburg virus disease therapeutics.
In addition, initiatives by government authorities to support the treatment of Marburg virus disease therapeutics, especially in hospitals, favor the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of Marburg virus disease therapeutics. Thus, the hospital segment is expected to hold a 45% market share of the Marburg virus disease therapeutics market in 2023.
Key players in the Marburg virus disease therapeutics market are Amicus Therapeutics, Inc, Alexion Pharmaceuticals, Inc, BioCryst Pharmaceuticals, Bavarian Nordic, Bio-Rad Laboratories, Inc, AlphaVax, GW Pharmaceuticals plc, Takeda Pharmaceutical Company Limited, Alexion Pharmaceuticals, Inc, Mapp Biopharmaceutical, Collaborations Pharmaceuticals, Inc, Emergent BioSolutions Inc, BioMarin and Sarepta Therapeutics, Alkido Pharma, Biofactura
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 90.74 Million |
| Market Value in 2033 | US$ 155 Million |
| Growth Rate | CAGR of 5.5% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Countries Profiled |
|
| Key Companies Profiled |
|
The marburg virus disease therapeutics market is valued at US$ 90.74 million In 2023.
The market is likely to experience a 5.5% CAGR until 2033.
The hospital segment is expected to dominate the market based on end user.
The market registered a CAGR of 4.1% from 2018 to 2022.
North America is estimated to dominate the market through 2033.
1. Executive Summary | Marburg Virus Disease Therapeutics Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Classification
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Drug Classification, 2018 to 2022
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Drug Classification, 2023 to 2033
5.3.1. Antiemetic
5.3.2. Nitro-glycerine
5.3.3. Loperamide
5.3.4. Antibiotics
5.3.5. Others
5.4. Y-o-Y Growth Trend Analysis By Drug Classification, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Classification, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Route of Administration
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Route of Administration, 2018 to 2022
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Route of Administration, 2023 to 2033
6.3.1. Injectable
6.3.2. Oral
6.3.3. Parenteral
6.4. Y-o-Y Growth Trend Analysis By Route of Administration, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Route of Administration, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End-Users
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) Analysis By End-Users, 2018 to 2022
7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By End-Users, 2023 to 2033
7.3.1. Hospitals
7.3.2. Specialty Clinics
7.3.3. Ambulatory Surgical Centres
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End-Users, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End-Users, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel
8.1. Introduction / Key Findings
8.2. Historical Market Size Value (US$ million) Analysis By Distribution Channel, 2018 to 2022
8.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Distribution Channel, 2023 to 2033
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022
8.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033
9. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
9.1. Introduction
9.2. Historical Market Size Value (US$ million) Analysis By Region, 2018 to 2022
9.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2023 to 2033
9.3.1. North America
9.3.2. Latin America
9.3.3. Europe
9.3.4. South Asia
9.3.5. East Asia
9.3.6. Oceania
9.3.7. Middle East and Africa (MEA)
9.4. Market Attractiveness Analysis By Region
10. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. The USA
10.2.1.2. Canada
10.2.2. By Drug Classification
10.2.3. By Route of Administration
10.2.4. By End-Users
10.2.5. By Distribution Channel
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Classification
10.3.3. By Route of Administration
10.3.4. By End-Users
10.3.5. By Distribution Channel
10.4. Key Takeaways
11. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Brazil
11.2.1.2. Mexico
11.2.1.3. Rest of Latin America
11.2.2. By Drug Classification
11.2.3. By Route of Administration
11.2.4. By End-Users
11.2.5. By Distribution Channel
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Classification
11.3.3. By Route of Administration
11.3.4. By End-Users
11.3.5. By Distribution Channel
11.4. Key Takeaways
12. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Germany
12.2.1.2. The United Kingdom
12.2.1.3. France
12.2.1.4. Spain
12.2.1.5. Italy
12.2.1.6. Rest of Europe
12.2.2. By Drug Classification
12.2.3. By Route of Administration
12.2.4. By End-Users
12.2.5. By Distribution Channel
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Classification
12.3.3. By Route of Administration
12.3.4. By End-Users
12.3.5. By Distribution Channel
12.4. Key Takeaways
13. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Rest of South Asia
13.2.2. By Drug Classification
13.2.3. By Route of Administration
13.2.4. By End-Users
13.2.5. By Distribution Channel
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Classification
13.3.3. By Route of Administration
13.3.4. By End-Users
13.3.5. By Distribution Channel
13.4. Key Takeaways
14. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. China
14.2.1.2. Japan
14.2.1.3. South Korea
14.2.2. By Drug Classification
14.2.3. By Route of Administration
14.2.4. By End-Users
14.2.5. By Distribution Channel
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Classification
14.3.3. By Route of Administration
14.3.4. By End-Users
14.3.5. By Distribution Channel
14.4. Key Takeaways
15. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
15.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
15.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
15.2.1. By Country
15.2.1.1. Australia
15.2.1.2. New Zealand
15.2.2. By Drug Classification
15.2.3. By Route of Administration
15.2.4. By End-Users
15.2.5. By Distribution Channel
15.3. Market Attractiveness Analysis
15.3.1. By Country
15.3.2. By Drug Classification
15.3.3. By Route of Administration
15.3.4. By End-Users
15.3.5. By Distribution Channel
15.4. Key Takeaways
16. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
16.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2018 to 2022
16.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2023 to 2033
16.2.1. By Country
16.2.1.1. GCC Countries
16.2.1.2. South Africa
16.2.1.3. Israel
16.2.1.4. Rest of MEA
16.2.2. By Drug Classification
16.2.3. By Route of Administration
16.2.4. By End-Users
16.2.5. By Distribution Channel
16.3. Market Attractiveness Analysis
16.3.1. By Country
16.3.2. By Drug Classification
16.3.3. By Route of Administration
16.3.4. By End-Users
16.3.5. By Distribution Channel
16.4. Key Takeaways
17. Key Countries Market Analysis
17.1. The USA
17.1.1. Pricing Analysis
17.1.2. Market Share Analysis, 2022
17.1.2.1. By Drug Classification
17.1.2.2. By Route of Administration
17.1.2.3. By End-Users
17.1.2.4. By Distribution Channel
17.2. Canada
17.2.1. Pricing Analysis
17.2.2. Market Share Analysis, 2022
17.2.2.1. By Drug Classification
17.2.2.2. By Route of Administration
17.2.2.3. By End-Users
17.2.2.4. By Distribution Channel
17.3. Brazil
17.3.1. Pricing Analysis
17.3.2. Market Share Analysis, 2022
17.3.2.1. By Drug Classification
17.3.2.2. By Route of Administration
17.3.2.3. By End-Users
17.3.2.4. By Distribution Channel
17.4. Mexico
17.4.1. Pricing Analysis
17.4.2. Market Share Analysis, 2022
17.4.2.1. By Drug Classification
17.4.2.2. By Route of Administration
17.4.2.3. By End-Users
17.4.2.4. By Distribution Channel
17.5. Germany
17.5.1. Pricing Analysis
17.5.2. Market Share Analysis, 2022
17.5.2.1. By Drug Classification
17.5.2.2. By Route of Administration
17.5.2.3. By End-Users
17.5.2.4. By Distribution Channel
17.6. The United Kingdom
17.6.1. Pricing Analysis
17.6.2. Market Share Analysis, 2022
17.6.2.1. By Drug Classification
17.6.2.2. By Route of Administration
17.6.2.3. By End-Users
17.6.2.4. By Distribution Channel
17.7. France
17.7.1. Pricing Analysis
17.7.2. Market Share Analysis, 2022
17.7.2.1. By Drug Classification
17.7.2.2. By Route of Administration
17.7.2.3. By End-Users
17.7.2.4. By Distribution Channel
17.8. Spain
17.8.1. Pricing Analysis
17.8.2. Market Share Analysis, 2022
17.8.2.1. By Drug Classification
17.8.2.2. By Route of Administration
17.8.2.3. By End-Users
17.8.2.4. By Distribution Channel
17.9. Italy
17.9.1. Pricing Analysis
17.9.2. Market Share Analysis, 2022
17.9.2.1. By Drug Classification
17.9.2.2. By Route of Administration
17.9.2.3. By End-Users
17.9.2.4. By Distribution Channel
17.10. India
17.10.1. Pricing Analysis
17.10.2. Market Share Analysis, 2022
17.10.2.1. By Drug Classification
17.10.2.2. By Route of Administration
17.10.2.3. By End-Users
17.10.2.4. By Distribution Channel
17.11. Malaysia
17.11.1. Pricing Analysis
17.11.2. Market Share Analysis, 2022
17.11.2.1. By Drug Classification
17.11.2.2. By Route of Administration
17.11.2.3. By End-Users
17.11.2.4. By Distribution Channel
17.12. Singapore
17.12.1. Pricing Analysis
17.12.2. Market Share Analysis, 2022
17.12.2.1. By Drug Classification
17.12.2.2. By Route of Administration
17.12.2.3. By End-Users
17.12.2.4. By Distribution Channel
17.13. Thailand
17.13.1. Pricing Analysis
17.13.2. Market Share Analysis, 2022
17.13.2.1. By Drug Classification
17.13.2.2. By Route of Administration
17.13.2.3. By End-Users
17.13.2.4. By Distribution Channel
17.14. China
17.14.1. Pricing Analysis
17.14.2. Market Share Analysis, 2022
17.14.2.1. By Drug Classification
17.14.2.2. By Route of Administration
17.14.2.3. By End-Users
17.14.2.4. By Distribution Channel
17.15. Japan
17.15.1. Pricing Analysis
17.15.2. Market Share Analysis, 2022
17.15.2.1. By Drug Classification
17.15.2.2. By Route of Administration
17.15.2.3. By End-Users
17.15.2.4. By Distribution Channel
17.16. South Korea
17.16.1. Pricing Analysis
17.16.2. Market Share Analysis, 2022
17.16.2.1. By Drug Classification
17.16.2.2. By Route of Administration
17.16.2.3. By End-Users
17.16.2.4. By Distribution Channel
17.17. Australia
17.17.1. Pricing Analysis
17.17.2. Market Share Analysis, 2022
17.17.2.1. By Drug Classification
17.17.2.2. By Route of Administration
17.17.2.3. By End-Users
17.17.2.4. By Distribution Channel
17.18. New Zealand
17.18.1. Pricing Analysis
17.18.2. Market Share Analysis, 2022
17.18.2.1. By Drug Classification
17.18.2.2. By Route of Administration
17.18.2.3. By End-Users
17.18.2.4. By Distribution Channel
17.19. GCC Countries
17.19.1. Pricing Analysis
17.19.2. Market Share Analysis, 2022
17.19.2.1. By Drug Classification
17.19.2.2. By Route of Administration
17.19.2.3. By End-Users
17.19.2.4. By Distribution Channel
17.20. South Africa
17.20.1. Pricing Analysis
17.20.2. Market Share Analysis, 2022
17.20.2.1. By Drug Classification
17.20.2.2. By Route of Administration
17.20.2.3. By End-Users
17.20.2.4. By Distribution Channel
17.21. Israel
17.21.1. Pricing Analysis
17.21.2. Market Share Analysis, 2022
17.21.2.1. By Drug Classification
17.21.2.2. By Route of Administration
17.21.2.3. By End-Users
17.21.2.4. By Distribution Channel
18. Market Structure Analysis
18.1. Competition Dashboard
18.2. Competition Benchmarking
18.3. Market Share Analysis of Top Players
18.3.1. By Regional
18.3.2. By Drug Classification
18.3.3. By Route of Administration
18.3.4. By End-Users
18.3.5. By Distribution Channel
19. Competition Analysis
19.1. Competition Deep Dive
19.1.1. Amicus Therapeutics, Inc.
19.1.1.1. Overview
19.1.1.2. Product Portfolio
19.1.1.3. Profitability by Market Segments
19.1.1.4. Sales Footprint
19.1.1.5. Strategy Overview
19.1.1.5.1. Marketing Strategy
19.1.2. Alexion Pharmaceuticals, Inc.
19.1.2.1. Overview
19.1.2.2. Product Portfolio
19.1.2.3. Profitability by Market Segments
19.1.2.4. Sales Footprint
19.1.2.5. Strategy Overview
19.1.2.5.1. Marketing Strategy
19.1.3. BioCryst Pharmaceuticals
19.1.3.1. Overview
19.1.3.2. Product Portfolio
19.1.3.3. Profitability by Market Segments
19.1.3.4. Sales Footprint
19.1.3.5. Strategy Overview
19.1.3.5.1. Marketing Strategy
19.1.4. Bavarian Nordic
19.1.4.1. Overview
19.1.4.2. Product Portfolio
19.1.4.3. Profitability by Market Segments
19.1.4.4. Sales Footprint
19.1.4.5. Strategy Overview
19.1.4.5.1. Marketing Strategy
19.1.5. Bio-Rad Laboratories, Inc.
19.1.5.1. Overview
19.1.5.2. Product Portfolio
19.1.5.3. Profitability by Market Segments
19.1.5.4. Sales Footprint
19.1.5.5. Strategy Overview
19.1.5.5.1. Marketing Strategy
19.1.6. AlphaVax
19.1.6.1. Overview
19.1.6.2. Product Portfolio
19.1.6.3. Profitability by Market Segments
19.1.6.4. Sales Footprint
19.1.6.5. Strategy Overview
19.1.6.5.1. Marketing Strategy
19.1.7. GW Pharmaceuticals plc.
19.1.7.1. Overview
19.1.7.2. Product Portfolio
19.1.7.3. Profitability by Market Segments
19.1.7.4. Sales Footprint
19.1.7.5. Strategy Overview
19.1.7.5.1. Marketing Strategy
19.1.8. Takeda Pharmaceutical Company Limited
19.1.8.1. Overview
19.1.8.2. Product Portfolio
19.1.8.3. Profitability by Market Segments
19.1.8.4. Sales Footprint
19.1.8.5. Strategy Overview
19.1.8.5.1. Marketing Strategy
19.1.9. Alexion Pharmaceuticals, Inc.
19.1.9.1. Overview
19.1.9.2. Product Portfolio
19.1.9.3. Profitability by Market Segments
19.1.9.4. Sales Footprint
19.1.9.5. Strategy Overview
19.1.9.5.1. Marketing Strategy
19.1.10. Mapp Biopharmaceutical
19.1.10.1. Overview
19.1.10.2. Product Portfolio
19.1.10.3. Profitability by Market Segments
19.1.10.4. Sales Footprint
19.1.10.5. Strategy Overview
19.1.10.5.1. Marketing Strategy
19.1.11. Collaborations Pharmaceuticals, Inc.
19.1.11.1. Overview
19.1.11.2. Product Portfolio
19.1.11.3. Profitability by Market Segments
19.1.11.4. Sales Footprint
19.1.11.5. Strategy Overview
19.1.11.5.1. Marketing Strategy
19.1.12. Emergent BioSolutions Inc.
19.1.12.1. Overview
19.1.12.2. Product Portfolio
19.1.12.3. Profitability by Market Segments
19.1.12.4. Sales Footprint
19.1.12.5. Strategy Overview
19.1.12.5.1. Marketing Strategy
19.1.13. BioMarin and Sarepta Therapeutics
19.1.13.1. Overview
19.1.13.2. Product Portfolio
19.1.13.3. Profitability by Market Segments
19.1.13.4. Sales Footprint
19.1.13.5. Strategy Overview
19.1.13.5.1. Marketing Strategy
19.1.14. Alkido Pharma
19.1.14.1. Overview
19.1.14.2. Product Portfolio
19.1.14.3. Profitability by Market Segments
19.1.14.4. Sales Footprint
19.1.14.5. Strategy Overview
19.1.14.5.1. Marketing Strategy
19.1.15. Biofactura
19.1.15.1. Overview
19.1.15.2. Product Portfolio
19.1.15.3. Profitability by Market Segments
19.1.15.4. Sales Footprint
19.1.15.5. Strategy Overview
19.1.15.5.1. Marketing Strategy
20. Assumptions & Acronyms Used
21. Research Methodology
Explore Healthcare Insights
View Reports
Marburg Virus Disease Therapeutics Market
